Cite
Gastrointestinal perforation after bevacizumab: a multi-site, single-institution study with a focus on survival.
MLA
Storandt, Michael H., et al. “Gastrointestinal Perforation after Bevacizumab: A Multi-Site, Single-Institution Study with a Focus on Survival.” World Journal of Surgical Oncology, vol. 21, no. 1, June 2023, pp. 1–7. EBSCOhost, https://doi.org/10.1186/s12957-023-03058-x.
APA
Storandt, M. H., Tran, N. H., Ehret, C. J., Hanna, M., Jochum, J., Moynagh, M. R., & Jatoi, A. (2023). Gastrointestinal perforation after bevacizumab: a multi-site, single-institution study with a focus on survival. World Journal of Surgical Oncology, 21(1), 1–7. https://doi.org/10.1186/s12957-023-03058-x
Chicago
Storandt, Michael H., Nguyen H. Tran, Christopher J. Ehret, Mina Hanna, Jacob Jochum, Michael R. Moynagh, and Aminah Jatoi. 2023. “Gastrointestinal Perforation after Bevacizumab: A Multi-Site, Single-Institution Study with a Focus on Survival.” World Journal of Surgical Oncology 21 (1): 1–7. doi:10.1186/s12957-023-03058-x.